Alpheus is a private, clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led, tumor-selective oncology approach designed to activate 5-ALA–derived protoporphyrin IX (PpIX), beginning with glioblastoma
Alpheus is a private, clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led, tumor-selective oncology approach designed to activate 5-ALA–derived protoporphyrin IX (PpIX), beginning with glioblastoma. PoMA is designed to enable localized pharmacologic activity through activation of tumor-localized porphyrin metabolites using proprietary low-intensity defocused ultrasound.